权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Optimizing Novel Immunotherapy Combinations Targeting the Tumor Microenvironment in Canine Spontaneous Osteosarcoma

优化针对犬自发性骨肉瘤肿瘤微环境的新型免疫治疗组合

基本信息

批准号：
10247894
负责人：
Steven W. Dow
金额：
$ 55.33万
依托单位：
COLORADO STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-09-30 至 2022-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10247894
关键词：
Active Immunotherapy Adjuvant Adjuvant Study Algorithms Animal Model Antibodies Biological Biological Assay Biological Markers Biological Response Modifiers Blood Canis familiaris Cells Clinical Clinical Trials Combination immunotherapy Crossover Design Data Disease Disease regression Drug Combinations Elements Exhibits Future Glutamine Goals Human IL6ST gene IL8 gene IL8RA gene Immune Immune Targeting Immune checkpoint inhibitor Immune response Immunologic Monitoring Immunologics Immunosuppression Immunotherapeutic agent Immunotherapy Interleukin-6 Lesion Limb structure Losartan Lung Malignant Neoplasms Malignant neoplasm of lung Measurement Metastatic Osteosarcoma Methods Microscopic Molecular Abnormality Mutation Neoplasm Metastasis Outcome Pattern Performance Pharmaceutical Preparations Pilot Projects Prevention Prodrugs Protocols documentation Randomized Clinical Trials Records Recurrence Regulatory T-Lymphocyte Resistance Safety Sampling Series Signal Transduction T-Lymphocyte Techniques Testing Therapeutic Tumor Immunity Tumor Tissue adaptive immune response anti-PD-1 anti-tumor immune response antibody inhibitor base chemotherapy clinical biomarkers effectiveness testing exhaust human model immune activation immune checkpoint blockade immunotherapy trials improved improved outcome inhibitor/antagonist limb amputation macrophage melanoma monocyte neoplasm immunotherapy neoplastic cell neutrophil novel osteosarcoma overexpression permissiveness pharmacokinetics and pharmacodynamics pilot trial pre-clinical prevent prospective recruit response small molecule small molecule inhibitor targeted treatment therapy resistant treatment response trial design tumor tumor DNA tumor growth tumor microenvironment

项目摘要

Project Abstract Spontaneous canine osteosarcoma (OS) is a well-defined large animal model of human OS, exhibiting similar clinical presentation and molecular aberrations. Indeed, canine OS has historically been used to help develop novel limb spare techniques, evaluate a variety of non-specific immunotherapeutics such as L-MTP-PE, and assess the efficacy of targeted therapeutics to prevent the outgrowth of metastatic disease. Despite best efforts, progress in the prevention and treatment of metastatic disease has essentially stalled for the past 3 decades; 30% of people and 90% of dogs still die of tumor spread, primarily to the lungs. Numerous clinical trials have been undertaken in people with macroscopic metastases and in dogs with both microscopic and macroscopic disease, yet all have failed to demonstrate improved outcomes. This is particularly evident with respect to immune checkpoint inhibitors that do not induce the dramatic disease regressions typically observed in other cancers such as melanoma and lung cancer. One particularly daunting challenge for immunotherapy-based therapeutics in OS relates to the permissiveness of the tumor microenvironment (TME) for inducing anti-tumor immune responses. Our data suggests that a relatively low mutational load combined with a dampened overall immune response in OS may contribute to the observed lack of response to current treatment approaches. We propose that targeting the immune suppressive TME in OS is essential to generating potent and durable anti- tumor immunity. To accomplish this, it may be necessary to simultaneously modulate several elements in the TME, including Tregs, MDSCs, M2 macrophages and overexpressed inhibitory checkpoint molecules. In support of this, we have generated a body of data demonstrating immunological activity of multiple therapeutics, including repurposed drugs with good safety records (losartan, oclacitinib), small molecule inhibitors with established PK/PD in dogs (toceranib, RV1001, reparixin, JHU-292) and antibodies specific for checkpoint molecules (anti- PD1). However, the exact combinations that are most effective against metastatic OS have not yet been identified, and this is a major goal of this proposal. As such, we hypothesize that an adaptive pilot trial design can be used to rapidly screen TME-targeting immunotherapy drug combinations in dogs with macroscopic chemotherapy-resistant metastatic OS and that this information can be refined to assess activity of the most active approach against microscopic metastases in a subsequent adjuvant trial. This will be accomplished by testing four TME modifying immunotherapy combinations for anti-tumor and immune modulatory activity in dogs with macroscopic OS metastases, interrogating relevant biomarkers associated with responses to therapy, then using this information to conduct an adjuvant immunotherapy trial with the most active combination in dogs with microscopic metastatic OS. The data generated from this proposal will create a blueprint for future immunotherapy studies in people with OS by eliminating approaches deemed inactive and generating a set of clinical biomarkers to guide treatment.

项目摘要